Evidence map›Paper›PMID 24769394›Full record

ArticleThe EMBO journal2014

Regulation of G6PD acetylation by SIRT2 and KAT9 modulates NADPH homeostasis and cell survival during oxidative stress.

Yi-Ping Wang, Li-Sha Zhou, Yu-Zheng Zhao, Shi-Wen Wang, Lei-Lei Chen, Li-Xia Liu, Zhi-Qiang Ling, Fu-Jun Hu, Yi-Ping Sun, Jing-Ye Zhang and 5 more

Open access · bronzeAbstract read
In one paragraph

Article in The EMBO journal, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 174 papers.

0numbers the graph read from it
0cells of the map it votes in
174citing papers in PubMed
13.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

174 citing papers in PubMed, 264 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Review
  13. Review
  14. The Yin-Yang balance of SIRT1 and SIRT2 in cancer metabolic remodeling.International journal of biological sciences · 2026
    Review
  15. Review
  16. Article
  17. Review
  18. Review
  19. Article
  20. Article

114 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

15 authors at 5 institutions in 2 countries.

Yi-Ping WangKey Laboratory of Molecular Medicine of Ministry of Education and Institutes of Biomedical Sciences, Shanghai Medical College College of Life Science Fudan University, Shanghai, China.
Li-Sha ZhouKey Laboratory of Molecular Medicine of Ministry of Education and Institutes of Biomedical Sciences, Shanghai Medical College College of Life Science Fudan University, Shanghai, China.
Yu-Zheng ZhaoSchool of Pharmacy East China University of Science and Technology, Shanghai, China.
Shi-Wen WangKey Laboratory of Molecular Medicine of Ministry of Education and Institutes of Biomedical Sciences, Shanghai Medical College College of Life Science Fudan University, Shanghai, China.
Lei-Lei ChenKey Laboratory of Molecular Medicine of Ministry of Education and Institutes of Biomedical Sciences, Shanghai Medical College College of Life Science Fudan University, Shanghai, China.
Li-Xia LiuKey Laboratory of Synthetic Biology, Bioinformatics Center and Laboratory of Systems Biology, Institute of Plant Physiology and Ecology Shanghai Institutes for Biological Sciences Chinese Academy of Sciences, Shanghai, China.
Zhi-Qiang LingZhejiang Cancer Research Institute, Zhejiang Province Cancer Hospital Zhejiang Cancer Center, Hangzhou, China.
Fu-Jun HuDepartment of Radiotherapy, Zhejiang Province Cancer Hospital Zhejiang Cancer Center, Hangzhou, China.
Yi-Ping SunKey Laboratory of Molecular Medicine of Ministry of Education and Institutes of Biomedical Sciences, Shanghai Medical College College of Life Science Fudan University, Shanghai, China.
Jing-Ye ZhangKey Laboratory of Molecular Medicine of Ministry of Education and Institutes of Biomedical Sciences, Shanghai Medical College College of Life Science Fudan University, Shanghai, China.
Chen YangKey Laboratory of Synthetic Biology, Bioinformatics Center and Laboratory of Systems Biology, Institute of Plant Physiology and Ecology Shanghai Institutes for Biological Sciences Chinese Academy of Sciences, Shanghai, China.
Yi YangSchool of Pharmacy East China University of Science and Technology, Shanghai, China.
Yue XiongKey Laboratory of Molecular Medicine of Ministry of Education and Institutes of Biomedical Sciences, Shanghai Medical College College of Life Science Fudan University, Shanghai, China Lineberger Comprehensive Cancer Center, Department of Biochemistry and Biophysics, University of North Carolina, Chapel Hill, NC, USA.
Kun-Liang GuanKey Laboratory of Molecular Medicine of Ministry of Education and Institutes of Biomedical Sciences, Shanghai Medical College College of Life Science Fudan University, Shanghai, China Department of Pharmacology and Moores Cancer Center, University of California San Diego, La Jolla, CA, USA.
Dan YeKey Laboratory of Molecular Medicine of Ministry of Education and Institutes of Biomedical Sciences, Shanghai Medical College College of Life Science Fudan University, Shanghai, China yedan@fudan.edu.cn.
Shanghai Medical College of Fudan University · CNCenter for Excellence in Molecular Plant Sciences · CNEast China University of Science and Technology · CNZhejiang Cancer Hospital · CNUniversity of California, San Diego · US

Funding

TSC2 tumor suppressor protein in cell energy responseR01CA108941 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI GUAN, KUN-LIANG · 2004 to 2015
$3.8M
Mechanisms of Metabolic Gene Mutations in CancerR01CA163834 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI BALDWIN, ALBERT SIDNEY · 2012 to 2023
$3.1M
NCI NIH HHS CA163834NCI NIH HHS R01 CA108941NCI NIH HHS R01CA108941NCI NIH HHS R01 CA163834
6 · The paper itself

Abstract

Glucose-6-phosphate dehydrogenase (G6PD) is a key enzyme in the pentose phosphate pathway (PPP) and plays an essential role in the oxidative stress response by producing NADPH, the main intracellular reductant. G6PD deficiency is the most common human enzyme defect, affecting more than 400 million people worldwide. Here, we show that G6PD is negatively regulated by acetylation on lysine 403 (K403), an evolutionarily conserved residue. The K403 acetylated G6PD is incapable of forming active dimers and displays a complete loss of activity. Knockdown of G6PD sensitizes cells to oxidative stress, and re-expression of wild-type G6PD, but not the K403 acetylation mimetic mutant, rescues cells from oxidative injury. Moreover, we show that cells sense extracellular oxidative stimuli to decrease G6PD acetylation in a SIRT2-dependent manner. The SIRT2-mediated deacetylation and activation of G6PD stimulates PPP to supply cytosolic NADPH to counteract oxidative damage and protect mouse erythrocytes. We also identified KAT9/ELP3 as a potential acetyltransferase of G6PD. Our study uncovers a previously unknown mechanism by which acetylation negatively regulates G6PD activity to maintain cellular NADPH homeostasis during oxidative stress.

Indexed as

AcetylationAnimalsCell SurvivalGene Knockdown TechniquesGlucosephosphate DehydrogenaseGreen Fluorescent ProteinsHEK293 CellsHistone AcetyltransferasesHomeostasisHumansMiceNADPNerve Tissue ProteinsOxidative StressRNA, Small InterferingSirtuin 2ELP3 protein, humanGlucosephosphate DehydrogenaseGreen Fluorescent ProteinsHistone AcetyltransferasesNADPNerve Tissue ProteinsRNA, Small InterferingSirt2 protein, mouseSirtuin 2acetylationG6PDnicotinamide adenine dinucleotide phosphatereactive oxygen speciesSIRT2

Identifiers

PMID24769394
PMCPMC4194121
OpenAlexW2102775608

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.